aTyr Pharma (NASDAQ:LIFE) Posts Earnings Results, Beats Expectations By $0.01 EPS

aTyr Pharma (NASDAQ:LIFE) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Yahoo Finance reports. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.11 million.

aTyr Pharma Price Performance

LIFE stock traded up $0.01 during midday trading on Friday, reaching $1.61. 258,232 shares of the stock were exchanged, compared to its average volume of 367,840. The stock has a market capitalization of $109.38 million, a PE ratio of -1.79 and a beta of 1.27. aTyr Pharma has a 52 week low of $1.08 and a 52 week high of $2.70. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.27 and a quick ratio of 6.27. The company has a fifty day moving average price of $1.77 and a 200 day moving average price of $1.55.

Wall Street Analysts Forecast Growth

LIFE has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of aTyr Pharma in a research report on Friday. Royal Bank of Canada dropped their price objective on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, aTyr Pharma has an average rating of “Hold” and a consensus target price of $23.67.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.